Honasa Consumer Ltd calls off proposed acquisition of Fluence Pharma Pvt Ltd
Honasa Consumer · Personal Products
Key highlights
- Proposed acquisition of 58% equity stake in Fluence Pharma was announced in June 2026
- Acquisition called off on August 25, 2026 due to non-fulfilment of closing conditions in Share Purchase Agreement
- Company remains committed to nutraceutical strategy and will explore other opportunities
Why it's rated notable: The cancellation of the previously announced 58% stake acquisition is definitive, but the filing states no deal amount, so the level stays at medium and the direction is neutral because the company says it will keep evaluating nutraceutical opportunities.
Original filing
Update On Proposed Acquisition Of Fluence Pharma Private Limited
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Honasa Consumer
- Acquisition / mergerNotableHonasa Consumer acquires 58% stake in Fluence Pharma to enter nutraceuticals
- Acquisition / mergerMajor developmentHonasa Consumer Limited announces audited FY26 results with unqualified audit opinion
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- 3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.